Chemical Engineering Journal, Год журнала: 2025, Номер unknown, С. 160431 - 160431
Опубликована: Фев. 1, 2025
Язык: Английский
Journal of Controlled Release, Год журнала: 2024, Номер 370, С. 256 - 276
Опубликована: Май 1, 2024
Язык: Английский
Процитировано
8
Journal of Cancer, Год журнала: 2023, Номер 14(5), С. 850 - 873
Опубликована: Янв. 1, 2023
Programmed death-1 is a protein found on the surface of immune cells that can interact with its ligand, programmed death-ligand 1 (PD-L1), which expressed plasma membrane, secreted cellular exosomes, in cell nuclei, or as circulating soluble protein. This interaction lead to escape cancer patients. In clinical settings, PD-L1 plays an important role tumor disease diagnosis, determining therapeutic effectiveness, and predicting patient prognosis. inhibitors are also essential components immunotherapy. Thus, detection levels crucial, especially era precision therapy. recent years, innovations have been made traditional immunoassay methods development new immunoassays for detection. review aims summarize research progress technology highlight applications PD-L1.
Язык: Английский
Процитировано
16
Nano Letters, Год журнала: 2024, Номер 24(15), С. 4354 - 4361
Опубликована: Апрель 2, 2024
The recent focus of cancer therapeutics research revolves around modulating the immunosuppressive tumor microenvironment (TME) to enhance efficacy. stroma, primarily composed cancer-associated fibroblasts (CAFs), poses significant obstacles therapeutic penetration, influencing resistance and progression. Reprogramming CAFs into an inactivated state has emerged as a promising strategy, necessitating innovative approaches. This study pioneers design nanoformulation using pioglitazone, Food Drug Administration-approved anti-diabetic drug, reprogram in breast TME. Glutathione (GSH)-responsive dendritic mesoporous organosilica nanoparticles loaded with pioglitazone (DMON-P) are designed for delivery cargo GSH-rich cytosol CAFs. DMON-P facilitates pioglitazone-mediated CAF reprogramming, enhancing penetration doxorubicin (Dox), drug. Treatment results downregulation biomarkers inhibits growth through effective Dox. approach holds promise alternative strategy outcomes CAF-abundant tumors, particularly cancer.
Язык: Английский
Процитировано
7
International Journal of Nanomedicine, Год журнала: 2024, Номер Volume 19, С. 4719 - 4733
Опубликована: Май 1, 2024
Introduction: Lung cancer's high incidence and dismal prognosis with traditional treatments like surgery radiotherapy necessitate innovative approaches. Despite advancements in nanotherapy, the limitations of single-treatment modalities significant side effects persist. To tackle lung cancer effectively, we devised a temperature-sensitive hydrogel-based local injection system near-infrared triggered drug release. Utilizing 2D MXene nanosheets as carriers loaded R837 cisplatin (DDP), encapsulated within hydrogel-forming PEG-MXene@DDP@R837@SHDS (MDR@SHDS), administered situ injections MDR@SHDS into tumor tissues combined photothermal therapy (PTT). The immune adjuvant enhances dendritic cell (DC) maturation phagocytosis, while PTT induces apoptosis necrosis by converting light energy heat energy. Methods: Material characterization employed transmission electron microscopy, X-ray photoelectron spectroscopy, phase transition temperature, thermography. In vitro experiments assessed Lewis proliferation using CCK-8, Edu, TUNEL assays. vivo on C57 mouse transplant tumors evaluated effect via thermography DC CD4+/CD8+ T ratios flow cytometry. anti-tumor efficacy was confirmed growth curve recording HE staining sections. Results: hydrogel exhibited excellent temperature sensitivity, controlled release properties, biocompatibility. revealed that had greater inhibitory compared to MDR@SHD alone. Combining immunotherapy, chemotherapy, yielded superior than individual treatments. Conclusion: MDR@SHDS, its simplicity, biocompatibility, enhanced combination PTT, presents promising therapeutic approach for treatment, offering potential clinical utility. Keywords: Mxene, delivery system, hydrogel,
Язык: Английский
Процитировано
6
Acta Pharmaceutica Sinica B, Год журнала: 2023, Номер 14(3), С. 1345 - 1361
Опубликована: Ноя. 5, 2023
A novel strategy of not only stimulating the immune cycle but also modulating immunosuppressive tumor microenvironment is vital importance to efficient cancer immunotherapy. Here, a new type spatiotemporal biomimetic "Gemini nanoimmunoregulators" was engineered activate robust systemic photoimmunotherapy by integrating triple-punch amplified immunogenic cell death (ICD), tumor-associated macrophages (TAMs) phenotype reprogramming and programmed ligand 1 (PD-L1) degradation. The PM@RM-T7 PR@RM-M2 were constructed taking biocompatible mesoporous polydopamine (mPDA) as nanovectors deliver metformin (Met) toll-like receptor 7/8 agonist resiquimod (R848) cells TAMs specific biorecognition via wrapping red blood membrane (RM) inlaid with T7 or M2 peptides. mPDA/Met@RM-T7 (abbreviated PM@RM-T7) elicit an in situ ICD effect through targeted PTT effectively stimulated anticancer immunity. Meanwhile, PD-L1 on remaining degraded burst prevent evasion. Subsequently, mPDA/R848@RM-M2 PR@RM-M2) specifically recognized reset from M1 state, thus disrupting further boosting function cytotoxic T lymphocytes. This pair sister nanoimmunoregulators cooperatively orchestrated comprehensive activity, which remarkably inhibited growth primary distant 4T1 tumors prevented malignant metastasis. study highlights cooperative modalities using multiple nanomedicines provides paradigm for immunotherapy against metastatic-prone tumors.
Язык: Английский
Процитировано
15
Acta Pharmaceutica Sinica B, Год журнала: 2023, Номер 14(1), С. 365 - 377
Опубликована: Авг. 19, 2023
Chemotherapy is one of the major approaches for treatment metastatic lung cancer, although it limited by low tumor delivery efficacy anticancer drugs. Bacterial therapy emerging cancer due to its high immune stimulation effect; however, excessively generated immunogenicity will cause serious inflammatory response syndrome. Here, we prepared cell membrane-coated liposomal paclitaxel-loaded bacterial ghosts (LP@BG@CCM) layer-by-layer encapsulation cancer. The preparation processes were simple, only involving film formation, electroporation, and pore extrusion. LP@BG@CCM owned much higher 4T1 toxicity than LP@BG faster fusion with cells. In breast mouse models, remarkably targeting intravenously injected was observed almost normalized appearance, reduced weight, clear tissue structure, enhanced apoptosis compared precursors. Moreover, several factors improved after administration LP@BG@CCM, including CD4+/CD8a+ T cells in spleen TNF-α, IFN-γ, IL-4 lung. exhibits optimal synergistic chemo-immunotherapy, which a promising medication
Язык: Английский
Процитировано
14
ACS Applied Bio Materials, Год журнала: 2024, Номер unknown
Опубликована: Июнь 26, 2024
The immune system is imperative to the survival of all biological organisms. A functional protects organism by detecting and eliminating foreign host aberrant molecules. Conversely, a dysfunctional characterized an overactive or weakened causes life-threatening autoimmune immunodeficiency diseases. Therefore, critical need exists develop technologies that regulate ensure homeostasis treat several Accumulating evidence shows biomaterials─artificial materials (polymers, metals, ceramics, engineered cells tissues) interact with systems─can trigger responses, offering science-based strategy modulate system. This Review discusses expanding frontiers biomaterial-based immunomodulation, focusing on principles for designing these materials. also presents examples immunomodulatory biomaterials, which include polymers metal- carbon-based nanomaterials, capable regulating innate adaptive systems.
Язык: Английский
Процитировано
5
Frontiers in Immunology, Год журнала: 2024, Номер 15
Опубликована: Авг. 14, 2024
With the COVID-19 pandemic, importance of vaccines has been widely recognized and led to increased research development efforts. Vaccines also play a crucial role in cancer treatment by activating immune system target destroy cells. However, enhancing efficacy remains challenge. Adjuvants, which enhance response antigens improve vaccine effectiveness, have faced limitations recent years, resulting few novel adjuvants being identified. The advancement artificial intelligence (AI) technology drug provided foundation for adjuvant screening application, leading diversification adjuvants. This article reviews significant tumor basic clinical explores use AI screen from databases. findings this review offer valuable insights new next-generation vaccines.
Язык: Английский
Процитировано
5
Frontiers in Immunology, Год журнала: 2023, Номер 14
Опубликована: Окт. 31, 2023
Following the success of cancer immunotherapy using large molecules against immune checkpoint inhibitors, concept small to interfere with intracellular negative regulators anti-tumor responses has emerged in recent years. The main targets for molecule drugs currently include enzymes feedback loops signaling pathways cells and proteins that promote immunosuppressive signals within tumor microenvironment. In adaptive system, T cell receptor (MAP4K1, DGKα/ζ, CBL-B, PTPN2, PTPN22, SHP1), co-receptor (CBL-B) cytokine (PTPN2) have been preclinically validated as promising initial clinical trials inhibitors are underway. To enhance innate responses, inhibitory immunomodulation cGAS/STING focus, ENPP1 TREX1 reached clinic. addition, via adenosine can be counteracted by CD39 CD73 inhibition, while suppression intratumoral prostaglandin E targeted EP2/EP4 antagonists. Here, we present status most drug candidates immunotherapy, all residing relatively early development, potential relevant biomarkers.
Язык: Английский
Процитировано
11
International Journal of Pharmaceutics, Год журнала: 2024, Номер 654, С. 123923 - 123923
Опубликована: Фев. 23, 2024
Язык: Английский
Процитировано
4